Our studies aiming to expand the potential clinical reach of FEN1 inhibitors beyond the HRD setting, identified EWS cells and more generally, SLFN11 expressing cancer cells, as potentially sensitive populations (Fig. 6E–G), which is consistent with the role of Schlafen-11 in response to RS-inducing DDRi/DDAs [84–86]. This evidence concerns the gene SLFN11 and cancer.